HUP0303921A2 - Dezoxipeganin alkalmazása pszihotrop anyagok okozta kóros központi idegrendszeri tünetek kezelésére - Google Patents

Dezoxipeganin alkalmazása pszihotrop anyagok okozta kóros központi idegrendszeri tünetek kezelésére

Info

Publication number
HUP0303921A2
HUP0303921A2 HU0303921A HUP0303921A HUP0303921A2 HU P0303921 A2 HUP0303921 A2 HU P0303921A2 HU 0303921 A HU0303921 A HU 0303921A HU P0303921 A HUP0303921 A HU P0303921A HU P0303921 A2 HUP0303921 A2 HU P0303921A2
Authority
HU
Hungary
Prior art keywords
nervous system
central nervous
psychotrops
desoxypeganine
intoxications
Prior art date
Application number
HU0303921A
Other languages
English (en)
Inventor
Frank Becher
Thomas Hille
Joachim Moormann
Klaus Opitz
Original Assignee
Hf Arzneimittelforschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682410&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0303921(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforschung Gmbh filed Critical Hf Arzneimittelforschung Gmbh
Publication of HUP0303921A2 publication Critical patent/HUP0303921A2/hu
Publication of HUP0303921A3 publication Critical patent/HUP0303921A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dezoxipeganin alkalmazása szabad bázisként vagy savaddiciós sókéntagyi, központi idegrendszeri vagy pszihiátriai tünetek, kiesésijelenségek vagy betegségek kezelésére, amelyek pszihotrop anyagokbevitele által alkalmi vagy krónikus, szenvedélyanyaggal,kábítószerrel vagy gyógyszerrel való visszaélés következtében, vagygyógyszerek rendeltetésszerű, főként ismételt vagy hosszantartóalkalmazása mellékhatásaként, vagy gyógyszerek nem rendeltetésszerű,főként ismételt vagy hosszantartó alkalmazása hatására, vagypszihotrop mérgező anyagok általi akut mérgezés, vagy pszihotrophatású mérgező anyagok krónikus hatására embernél vagy másgerinceseknél lépnek fel. Ó
HU0303921A 2001-04-24 2002-04-18 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops HUP0303921A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119863A DE10119863A1 (de) 2001-04-24 2001-04-24 Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
PCT/EP2002/004278 WO2002087553A2 (de) 2001-04-24 2002-04-18 Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (2)

Publication Number Publication Date
HUP0303921A2 true HUP0303921A2 (hu) 2004-03-01
HUP0303921A3 HUP0303921A3 (en) 2011-03-28

Family

ID=7682410

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303921A HUP0303921A3 (en) 2001-04-24 2002-04-18 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops

Country Status (28)

Country Link
US (1) US20040132751A1 (hu)
EP (1) EP1383503B1 (hu)
JP (1) JP2004526791A (hu)
KR (1) KR20030094365A (hu)
CN (1) CN1638774A (hu)
AR (1) AR033469A1 (hu)
AT (1) ATE411024T1 (hu)
AU (1) AU2002325209B2 (hu)
BR (1) BR0209125A (hu)
CA (1) CA2445132C (hu)
CZ (1) CZ20032788A3 (hu)
DE (2) DE10119863A1 (hu)
DK (1) DK1383503T3 (hu)
EA (1) EA200301134A1 (hu)
ES (1) ES2316595T3 (hu)
HK (1) HK1062402A1 (hu)
HU (1) HUP0303921A3 (hu)
IL (1) IL158383A0 (hu)
MX (1) MXPA03009766A (hu)
MY (1) MY135676A (hu)
NO (1) NO20034741L (hu)
NZ (1) NZ529005A (hu)
PL (1) PL366845A1 (hu)
PT (1) PT1383503E (hu)
SI (1) SI1383503T1 (hu)
SK (1) SK287214B6 (hu)
WO (1) WO2002087553A2 (hu)
ZA (1) ZA200308042B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
ES2360547B1 (es) * 2009-11-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (hu) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19924951B4 (de) * 1999-05-31 2004-02-05 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine

Also Published As

Publication number Publication date
HUP0303921A3 (en) 2011-03-28
SK287214B6 (sk) 2010-03-08
CA2445132C (en) 2009-01-13
ATE411024T1 (de) 2008-10-15
CA2445132A1 (en) 2002-11-07
SI1383503T1 (sl) 2009-04-30
AR033469A1 (es) 2003-12-17
NO20034741D0 (no) 2003-10-23
WO2002087553A3 (de) 2003-02-27
IL158383A0 (en) 2004-05-12
ZA200308042B (en) 2004-02-04
CZ20032788A3 (en) 2004-05-12
EA200301134A1 (ru) 2004-04-29
DE10119863A1 (de) 2002-11-07
HK1062402A1 (en) 2004-11-05
WO2002087553A2 (de) 2002-11-07
CN1638774A (zh) 2005-07-13
BR0209125A (pt) 2004-07-27
DE50212901D1 (de) 2008-11-27
EP1383503B1 (de) 2008-10-15
EP1383503A2 (de) 2004-01-28
ES2316595T3 (es) 2009-04-16
AU2002325209B2 (en) 2007-08-16
MY135676A (en) 2008-06-30
JP2004526791A (ja) 2004-09-02
PT1383503E (pt) 2009-01-07
KR20030094365A (ko) 2003-12-11
NZ529005A (en) 2007-11-30
DK1383503T3 (da) 2009-02-16
US20040132751A1 (en) 2004-07-08
SK13162003A3 (sk) 2004-02-03
NO20034741L (no) 2003-10-23
MXPA03009766A (es) 2005-04-19
PL366845A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
CY1110391T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
ATE510541T1 (de) Zusammensetzung zur verbesserten bioverfügbarkeit und zur erhöhten freisetzung von 5,5-diphenyl- barbitursäure im gehirn
HUP0303921A2 (hu) Dezoxipeganin alkalmazása pszihotrop anyagok okozta kóros központi idegrendszeri tünetek kezelésére
IL194346A0 (en) Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application
MXPA03009765A (es) Utilizacion de galantamina para el tratamiento de patologias del sistema nervioso central originadas por intoxicaciones con sustancias psicotropicas.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
RU2001126651A (ru) Способ лечения отечной макулопатии
RU2003112906A (ru) Способ лечения акантолической пузырчатки
TH64669A (th) สารประกอบชนิดใหม่
TH50298A (th) สารประกอบที่เกี่ยวข้องกับระบบการควบคุมจังหวะประจำวัน
RU98103406A (ru) Способ лечения вибрационной болезни
UA42194A (uk) Спосіб введення лікарських препаратів, зосереджених в еритроцитарних контейнерах
TH60393A (th) การบัดบัดรักษาอาการเจ็บปวด
RU2002113511A (ru) Способ лечения одонтогенной аденофлегмоны
RU2003138011A (ru) Способ лечения хронического пиелонефрита
RU2004130974A (ru) Способ лечения воспалительной реакции глаза
TH37491A (th) วิธีการบำบัดรักษาโรคหลอดลมอักเสบเรื้อรัง โดยใช้สารประกอบอินดอล
TH81176A (th) วิธีการรักษาและป้องกัน
RU2001125131A (ru) Способ лечения кератопатии
RU2002101630A (ru) Способ лечения эндометрита у коров

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished